MicroPort Scientific Corporation - Asset Resilience Ratio
MicroPort Scientific Corporation (MSK) has an Asset Resilience Ratio of 3.06% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read MicroPort Scientific Corporation debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2013–2024)
This chart shows how MicroPort Scientific Corporation's Asset Resilience Ratio has changed over time. See MicroPort Scientific Corporation shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down MicroPort Scientific Corporation's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see MicroPort Scientific Corporation market cap and net worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €115.56 Million | 3.06% |
| Total Liquid Assets | €115.56 Million | 3.06% |
Asset Resilience Insights
- Limited Liquidity: MicroPort Scientific Corporation maintains only 3.06% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
MicroPort Scientific Corporation Industry Peers by Asset Resilience Ratio
Compare MicroPort Scientific Corporation's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Demant A/S
CO:DEMANT |
Medical Devices | -2.59% |
|
Sino Medical Sciences Technology In
SHG:688108 |
Medical Devices | 0.66% |
|
Polynovo Ltd
AU:PNV |
Medical Devices | 5.46% |
|
Beijing Succeeder Technology Inc
SHG:688338 |
Medical Devices | 28.66% |
|
Tellgen Corp
SHE:300642 |
Medical Devices | 8.60% |
|
Respiri Ltd
AU:RSH |
Medical Devices | 0.46% |
|
Diagnostic Medical Systems SA
PA:ALDMS |
Medical Devices | 1.39% |
|
Duearity AB
ST:DEAR |
Medical Devices | 145.62% |
Annual Asset Resilience Ratio for MicroPort Scientific Corporation (2013–2024)
The table below shows the annual Asset Resilience Ratio data for MicroPort Scientific Corporation.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 7.20% | €261.49 Million ≈ $305.70 Million |
€3.63 Billion ≈ $4.25 Billion |
+0.59pp |
| 2023-12-31 | 6.61% | €259.95 Million ≈ $303.91 Million |
€3.93 Billion ≈ $4.60 Billion |
+5.65pp |
| 2022-12-31 | 0.96% | €38.20 Million ≈ $44.66 Million |
€3.99 Billion ≈ $4.67 Billion |
0.00pp |
| 2018-12-31 | 0.96% | €12.21 Million ≈ $14.28 Million |
€1.27 Billion ≈ $1.49 Billion |
-0.34pp |
| 2017-12-31 | 1.30% | €11.71 Million ≈ $13.70 Million |
€903.62 Million ≈ $1.06 Billion |
+0.84pp |
| 2016-12-31 | 0.45% | €3.50 Million ≈ $4.09 Million |
€774.55 Million ≈ $905.53 Million |
-1.37pp |
| 2015-12-31 | 1.83% | €13.40 Million ≈ $15.66 Million |
€733.64 Million ≈ $857.71 Million |
-2.35pp |
| 2014-12-31 | 4.17% | €39.23 Million ≈ $45.86 Million |
€939.73 Million ≈ $1.10 Billion |
-3.68pp |
| 2013-12-31 | 7.86% | €40.76 Million ≈ $47.65 Million |
€518.85 Million ≈ $606.59 Million |
-- |
About MicroPort Scientific Corporation
MicroPort Scientific Corporation, together with its subsidiaries, engages in the innovating, manufacturing, and marketing medical devices globally in the People's Republic of China, Europe, Middle East and Africa, Japan, and internationally. The company's Cardiovascular Devices segment offers medical solutions for the treatment of coronary artery-related diseases; and coronary stents, related del… Read more